Non-alcoholic Steatohepatitis Treatment Market - 2025-2031

November 2025 | 65 pages | ID: N21D5997818CEN
DataM Intelligence

Abstracts

Non-alcoholic Steatohepatitis Treatment Marketis is growing with a CAGR of 54.00% during the forecast period 2026-2035.

The Non-alcoholic Steatohepatitis Treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Non-alcoholic Steatohepatitis Treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By DRUG

• Vitamin E
• Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib & Cenicriviroc
• Others

By DISTRIBUTION CHANNELS

• Hospital pharmacy
• Retail pharmacy
• Online providers

Regional Analysis for Non-alcoholic Steatohepatitis Treatment Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Non-alcoholic Steatohepatitis Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. SCOPE AND METHODOLOGY

1.1. Research Methodology
1.2. Scope of the market

2. KEY TRENDS AND DEVELOPMENTS

2.1. Key Trends and Developments

3. EXECUTIVE SUMMARY

3.1. Market Snippet By Distribution Channels
3.2. Market Snippet By Drug
3.3. Market Snippet By Region
3.4. DataM CLO Scenario

4. GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) TREATMENT MARKET DYNAMICS

4.1. Market impacting factors
4.2. Drivers
  4.2.1. Rise in NASH-affected population
  4.2.2. Increasing prevalence of diabetes & obesity
  4.2.3. Driver
4.3. Restraints
  4.3.1. Insufficient diagnostic technologies for NASH
  4.3.2. Restraint
4.4. Opportunity
4.5. Impact analysis

5. INDUSTRY ANALYSIS

5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Pipeline analysis

6. BY DRUG

6.1. Introduction
6.2. Market size analysis, and y-o-y growth analysis (%), By Drug segment
6.3. Market attractiveness index, By Drug segment
6.4. Vitamin E
  6.4.1. Introduction
  6.4.2. Market size analysis, y-o-y growth analysis (%)
6.5. Pioglitazone
6.6. Ocaliva
6.7. Elafibranor
6.8. Selonsertib & Cenicriviroc
6.9. Others

7. BY DISTRIBUTION CHANNELS

7.1. Introduction
7.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channels segment
7.3. Market attractiveness index, By Distribution Channels segment
7.4. Hospital pharmacy
  7.4.1. Introduction
  7.4.2. Market size analysis, and y-o-y growth analysis (%)
7.5. Retail pharmacy
7.6. Online providers

8. BY REGION

8.1. Introduction
8.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
8.3. Market Attractiveness Index, By Region
8.4. North America
  8.4.1. Introduction
  8.4.2. Key region-specific dynamics
  8.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
  8.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
  8.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    8.4.5.1. U.S.
    8.4.5.2. Canada
    8.4.5.3. Mexico
8.5. Europe
  8.5.1. Introduction
  8.5.2. Key Region-Specific Dynamics
  8.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
  8.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
  8.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    8.5.5.1. Germany
    8.5.5.2. U.K.
    8.5.5.3. France
    8.5.5.4. Italy
    8.5.5.5. Spain
    8.5.5.6. Rest of Europe
8.6. South America
  8.6.1. Introduction
  8.6.2. Key Region-Specific Dynamics
  8.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
  8.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
  8.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    8.6.5.1. Brazil
    8.6.5.2. Argentina
    8.6.5.3. Rest of South America
8.7. Asia Pacific
  8.7.1. Introduction
  8.7.2. Key Region-Specific Dynamics
  8.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
  8.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
  8.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    8.7.5.1. China
    8.7.5.2. India
    8.7.5.3. Japan
    8.7.5.4. Australia
    8.7.5.5. Rest of Asia Pacific
8.8. The Middle East And Africa
  8.8.1. Introduction
  8.8.2. Key Region-Specific Dynamics
  8.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
  8.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

9. COMPETITIVE LANDSCAPE

9.1. Competitive scenario
9.2. Competitor strategy analysis
9.3. Comparative type portfolio analysis
9.4. Market positioning/share analysis
9.5. Mergers and acquisitions analysis

10. COMPANY PROFILES

10.1. Allergan plc.
  10.1.1. Company Overview
  10.1.2. Type Portfolio And Description
  10.1.3. Key Highlights
  10.1.4. Financial Overview
10.2. Pfizer Inc
10.3. Gilead Sciences, Inc.
10.4. Genfit SA
10.5. Novartis AG
10.6. Intercepts Pharmaceuticals
10.7. Cadila Healthcare Ltd
10.8. Novo Nordisk
10.9. Raptor Pharmaceutical Corp.
10.10. Galmed Pharmaceuticals Ltd.

11. PREMIUM INSIGHTS

12. DATAM INTELLIGENCE

12.1. Appendix
12.2. About us and services
12.3. Contact Us